HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/β-1,3-glucan complex
Keita Yamana, Riku Kawasaki, Kousuke Kondo, H. Hirano, Shogo Kawamura, Yu Sanada, Kaori Bando, Anri Tabata, Hideki Azuma, Takushi Takata, Yoshinori Sakurai, Hiroki Tanaka, Tomoki Kodama, Seiji Kawamoto, Takeshi Nagasaki, Atsushi Ikeda
Abstract
The development of boron agents with integrated functionality, including biocompatibility, high boron content, and cancer cell targeting, is desired to exploit the therapeutic efficacy of boron neutron capture therapy (BNCT). Here, we report the therapeutic efficacy of BNCT using a HER-2-targeted antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. The anticancer effect of BNCT using our system was 30-fold that of the clinically available boron agent l-BPA/fructose complex.
Topics & Concepts
BoronBoron nitrideBiocompatibilityConjugated systemMaterials scienceNeutron captureNanotechnologyRadiochemistryChemistryPolymerOrganic chemistryMetallurgyComposite materialBoron Compounds in ChemistryBoron and Carbon Nanomaterials ResearchRadiopharmaceutical Chemistry and Applications